A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice

CompletedOBSERVATIONAL
Enrollment

187

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

April 6, 2024

Study Completion Date

April 6, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Semaglutide

Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.

Trial Locations (2)

44670

Centro de Investigacion Clinica Endocrinologica de Jalisco, Guadalajara

CICEJ Centro de Investigacion Clinica Endocrinologica de Jalisco SC, Guadalajara

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05316662 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice | Biotech Hunter | Biotech Hunter